Project Grant R01AR084841
Award Date
9/10/24
Completion Date
7/31/29
Dollars Obligated
$531K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to develop improved gene replacement and editing therapies for Duchenne muscular dystrophy (DMD). The total award amount is $671,240 and the project period runs from January 22, 2025 to December 31, 2029. The key research objectives are to: 1) Refine technologies for expressing...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $221,100 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Massachusetts Medical School to develop and evaluate in vivo gene editing strategies to repair collagen mutations in mouse models of osteogenesis imperfecta (OI). The 2-year project aims to use bone-targeting recombinant adeno-associated virus (rAAV) to implement precise gene editing...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the functional roles of microRNA-320 (miR-320) in skeletal muscle. The $374,204 award to The Leland Stanford Junior University will fully characterize a muscle-specific miR-320 knockout mouse model, examine the underlying mechanisms of the observed muscle wasting...
This Project Grant award of $488,575 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to understand how myosin binding protein-C (MyBP-C) regulates skeletal muscle contraction and the effects of mutations in genes encoding slow and fast MyBP-C paralogs. The University of Arizona, serving as the prime awardee, will use a novel "cut and paste"...
This Project Grant award of $1,222,648.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The award will fund research by Cornell University over a 5-year period starting on Sep 1, 2024 to identify the mechanism responsible for "ultra-rapid" induction of mechanoresponsive genes and determine the functional consequences of impaired...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the novel role of HOX-expressing interstitial cells in muscle growth, homeostasis, and regeneration. The $557,357 award, effective March 14, 2025 through February 28, 2030, will be used by the University of Wisconsin-Madison to interrogate the potential of...
This Project Grant award of $151,471.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The project aims to investigate the use of collagenase enzyme to target and modify collagen architecture in fibrotic skeletal muscle, with the goal of reducing muscle stiffness and promoting tissue regeneration. Key research activities include: 1) using second...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $439,791.00 over a 5-year period from March 1, 2025 to February 28, 2030 to The University of Texas Southwestern Medical Center. The funding will support research to investigate the molecular mechanisms underlying myoblast fusion, which is essential for skeletal muscle development and...
This Project Grant award of $522,714 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of stretch activation in mammalian skeletal muscle endurance. The research will focus on measuring the characteristics and mechanisms of stretch activation in mouse slow-twitch and fast-twitch muscle fibers, including determining the specific myosin...
This $420,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Myogene Bio LLC, a woman-owned small biotechnology company, to evaluate the efficacy of CRISPR gene editing technology in treating Duchenne muscular dystrophy (DMD). The research aims to correlate CRISPR efficacy with functional outcomes in preclinical DMD models, building on the company's previous federal grant awards focused...